{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:04:10Z","timestamp":1790960650006,"version":"4.1.0"},"reference-count":25,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IDR"],"DOI":"10.2147\/idr.s516991","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T09:20:13Z","timestamp":1751620813000},"page":"3307-3315","source":"Crossref","is-referenced-by-count":10,"title":["Safety and Tolerability of Contezolid Versus Linezolid for Short-Term Treatment of Rifampicin-Resistant Pulmonary Tuberculosis: A Randomized Controlled Study"],"prefix":"10.2147","volume":"Volume 18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0743-7964","authenticated-orcid":true,"given":"Jun","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjuan","family":"Nie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8460-6047","authenticated-orcid":true,"given":"Liping","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naihui","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yadong","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,7]]},"reference":[{"key":"ref1","unstructured":"World Health Organization. Global tuberculosis report 2023. Available from: https:\/\/www.who.int\/teams\/global-tuberculosis-programme\/tb-reports\/global-tuberculosis-report-2023. Accessed December 1, 2023."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1700311","DOI":"10.1183\/13993003.00311-2017","volume":"50","author":"Hafkin","year":"2017","journal-title":"Eur Respir J"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.ajic.2015.12.042","volume":"44","author":"Zhang","year":"2016","journal-title":"Am J Infect Control"},{"key":"ref4","unstructured":"World Health Organization. 2020. WHO consolidated guidelines on tuberculosis: drug-resistant tuberculosis treatment. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789241550529. Accessed December 1, 2023."},{"key":"ref5","unstructured":"Beijing Chest Hospital, Capital Medical University\/Beijing Tuberculosis and Thoracic Tumor Research Institute, Chinese Antituberculosis Association, Editorial Board of Chinese Journal of Antituberculosis. Chinese expert consensus on the all-oral treatment of drug-resistant pulmonary tuberculosis (2021 Edition in Chinese). Chin J Antituberculosis. 2021;43:859\u2013866."},{"key":"ref6","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1056\/NEJMoa1901814.02","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"S101","DOI":"10.1016\/j.ijtb.2023.04.006","volume":"71 Suppl 1","author":"Mishra","year":"2024","journal-title":"Indian J Tuberc"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1587","DOI":"10.1007\/s40265-021-01576-0","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e00493","DOI":"10.1128\/AAC.00493-18","volume":"62","author":"Shoen","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"e0462722","DOI":"10.1128\/spectrum.04627-22","volume":"11","author":"An","year":"2023","journal-title":"Microbiol Spectr"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1157437","DOI":"10.3389\/fphar.2023.1157437","volume":"14","author":"Li","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref12","unstructured":"U.S. Department of Health and Human Services. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. Available from: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf. Accessed June 1, 2023."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"4487","DOI":"10.1021\/jm401931e","volume":"57","author":"Gordeev","year":"2014","journal-title":"J Med Chem"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.clinthera.2017.12.017","volume":"40","author":"Wu","year":"2018","journal-title":"Clin Ther"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/jac\/dkac073","volume":"77","author":"Zhao","year":"2022","journal-title":"J Antimicrob Chemother"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"1135007","DOI":"10.3389\/fphar.2023.1135007","volume":"14","author":"Wu","year":"2023","journal-title":"Front Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.clinthera.2019.04.025","volume":"41","author":"Wu","year":"2019","journal-title":"Clin Ther"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1093\/cid\/ciad051","volume":"76","author":"Solans","year":"2023","journal-title":"Clin Infect Dis"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.2147\/IDR.S425743","volume":"16","author":"Wang","year":"2023","journal-title":"Infect Drug Resist"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1224179","DOI":"10.3389\/fmed.2023.1224179","volume":"10","author":"Xu","year":"2023","journal-title":"Front Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1258561","DOI":"10.3389\/fcimb.2023.1258561","volume":"13","author":"Li","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"106875","DOI":"10.1016\/j.ijantimicag.2023.106875","volume":"62","author":"Guo","year":"2023","journal-title":"Int J Antimicrob Agents"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"99","DOI":"10.5582\/ddt.2022.01025","volume":"16","author":"Yang","year":"2022","journal-title":"Drug Discov Ther"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"431","DOI":"10.4103\/1995-7645.329004","volume":"14","author":"Mishra","year":"2021","journal-title":"Asian Pac J Trop Med"},{"key":"ref25","unstructured":"WHO Handbook on Tuberculosis. Module 4: treatment - Drug-Resistant Tuberculosis Treatment. Geneva: World Health Organization, 2020. Available from: https:\/\/www.who.int\/publications\/i\/item\/9789240069236. Accessed December 30, 2024."}],"container-title":["Infection and Drug Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/article\/download\/104487","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/article\/download\/104487","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T09:20:16Z","timestamp":1751620816000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/safety-and-tolerability-of-contezolid-versus-linezolid-for-short-term--peer-reviewed-fulltext-article-IDR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":25,"URL":"https:\/\/doi.org\/10.2147\/idr.s516991","relation":{},"ISSN":["1178-6973"],"issn-type":[{"value":"1178-6973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]}}}